Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The c-Myc Oncoprotein Interacts with Bcr.

Gwendolyn M Mahon1, Yan Wang, Malgorzata Korus

  • 1Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School, PO Box 1709, 225 Warren Street, Newark, NJ 07101-1709, USA.

Current Biology : CB
|March 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients.

Journal for immunotherapy of cancer·2025
Same author

NKG2D receptor signaling shapes T cell thymic education.

Journal of leukocyte biology·2023
Same author

CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies.

iScience·2023
Same author

Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC.

International journal of molecular sciences·2021
Same author

Engineering the interface in graphene oxide/epoxy composites using bio-based epoxy-graphene oxide nanomaterial to achieve superior anticorrosion performance.

Journal of colloid and interface science·2020
Same author

A rare entity of Primary Ewing sarcoma in kidney.

BMC surgery·2020

The Bcr protein limits the activity of c-Myc, a key factor in Philadelphia chromosome-positive leukemias. Bcr reduces c-Myc protein levels, suggesting it regulates c-Myc stability and may contribute to leukemia development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Bcr is a fusion partner for Abl (p210 Bcr-Abl) in Philadelphia chromosome-positive leukemias.
  • c-Myc is a transcription factor implicated in cell proliferation and cancer.
  • The interaction between Bcr and c-Myc in leukemogenesis is not fully understood.

Purpose of the Study:

  • To investigate the interaction between Bcr and c-Myc.
  • To determine the functional consequences of Bcr expression on c-Myc activity.
  • To elucidate the role of Bcr as a regulator of c-Myc in leukemia.

Main Methods:

  • Yeast and mammalian cell-based interaction assays.
  • Co-immunoprecipitation to detect protein interactions.
  • Analysis of gene expression and cellular transformation.

Related Experiment Videos

  • Western blotting to assess protein levels and localization.

    • Main Results:

    • Bcr directly binds to c-Myc in yeast and mammalian cells, including leukemic cell lines.
    • Bcr does not interact with Max or the c-Myc.Max heterodimer.
    • Bcr expression inhibits c-Myc-responsive genes and H-Ras-induced transformation.
    • Bcr does not prevent c-Myc nuclear localization but reduces c-Myc protein levels, suggesting regulation of stability.
    • Increased Bcr dosage correlates with decreased c-Myc protein levels.

    Conclusions:

    • Bcr is a novel regulator of c-Myc function.
    • Bcr limits c-Myc activity by potentially regulating its protein stability.
    • Disrupted Bcr expression may contribute to elevated c-Myc levels in Bcr-Abl transformed cells, promoting leukemogenesis.